MiNK Therapeutics, Inc. entered into a stock purchase agreement for issuance of 4,640,000 common shares at a price of $1.25 per share for gross proceeds of $5,800,000 on May 13, 2024. The transaction is expected to close on May 14, 2024, subject to customary closing conditions.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.94 USD | -2.09% | -5.05% | -12.15% |
May. 14 | Transcript : MiNK Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.15% | 33.32M | |
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- INKT Stock
- News MiNK Therapeutics, Inc.
- MiNK Therapeutics, Inc. announced that it expects to receive $5.8 million in funding